Fabrication, optimisation and in vitro evaluation of docetaxel and curcumin Co-loaded nanostructured lipid carriers for improved antitumor activity against non-small cell lung carcinoma

  • J Microencapsul. 2020 Dec;37(8):543-556. doi: 10.1080/02652048.2020.1823498.
Shruti Rawal  1 ,  Bhoomika Patel  1 ,  Mayur M Patel  1
Affiliations
  • 1. Department of Pharmaceutics, Institute of Pharmacy, Nirma University, Ahmedabad, India.
PMID: 32924677 DOI: 10.1080/02652048.2020.1823498
Abstract

Aim: To develop docetaxel (DT) and curcumin (CUR) co-loaded nanostructured lipid carriers (DTCR-NLCs) for ratiometric co-targeting to non-small cell lung carcinoma (NSCLC) cells.

Methods: The DTCR-NLCs were developed by employing a high-pressure homogenisation technique and optimised by employing a rotatable central composite design response surface methodology (RCCD-RSM) via the design of experiments (DoE) approach.

Results: The optimised DTCR-NLCs had a particle size (D90) of 150.2 ± 5.2 nm, PDI of 0.263 ± 0.15, zeta potential of +26.3 ± 5.2 mv. The % drug loading (% DL) of DT and CUR was observed to be 1.38 ± 0.98 and 2.99 ± 1.24, respectively. Dissolution studies depicted a pH-independent drug release (≈98% drug release at 144 h). The DTCR-NLCs were stable and haemocompatible. MTT cell viability assay of DTCR-NLCs demonstrated considerably increased cytotoxicity towards NCI-H460 cells.

Conclusions: The developed DTCR-NLCs heralds the future of an efficacious and safer Taxane therapy for NSCLC.

Keywords
NCI-H460; NSCLC; Rotatable central composite design; Weibull kinetics; synergistic.
Products